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Abstract
Postponement of child bearing and maternal age at first pregnancy are on the rise, contributing considerably to an
increase in age-related infertility and the demand for assisted reproductive technologies (ART) treatment. This brings
to the infertility clinics many women with low ovarian reserve and poor ovarian response (POR) to
conventional stimulation. The Bologna criteria were released to standardize the definition of POR and pave
the way for the formulation of evidence-based, efficient modalities of treatment for women undergoing IVF-
ET. More than four years have passed since the introduction of these criteria and the debate is still ongoing
whether a revision is due. Women with POR comprise several sub-groups with diverse baseline distinctiveness,
a major issue that has fueled the discussion. Although antral follicle count (AFC) and anti-Müllerian hormone
(AMH), are considered good predictors of ovarian reserve, their threshold values are still not universally
standardized. Different definitions for sonographic AFC and diverse assays for AMH are held responsible for
this delay in standardization. Adding established risk factors to the criteria will lead to more reliable and
reproducible definition of a POR, especially in young women. The original criteria did not address the issue of
oocyte quality, and the addition of risk factors may yield specific associations with quality vs. quantity.
Patient’s age is the best available criterion, although limited, to predict live-birth and presumably oocyte
quality. High scale studies to validate these criteria are still missing while recent evidence raises concern
regarding over diagnosis.
Keywords: Poor ovarian response, Bologna criteria, Low ovarian reserve, Ovarian ageing, ART
Background
Maternal age at first pregnancy and age-related infer-
tility are steadily increasing and the consequent de-
mand for assisted reproductive technologies (ART) is
on the rise [1–3]. Postponement of child bearing is
common in the industrialized countries. This brings
to the infertility clinics many women who are beyond
the optimal age for conception. Hence, many are pre-
senting with a diminished response to the standard
stimulation protocols. The European Society of Hu-
man Reproduction and Embryology (ESHRE) pub-
lished the Bologna criteria in 2011 in order to
standardize the definition of poor ovarian response
(POR) in a simple and reproducible manner [4]. Till
that time the variability in the definition of POR has
been striking [5]. The main purpose of the uniform
criteria was to develop evidence-based efficient and
appropriate protocols or modalities of treatment for
such women undergoing IVF-ET treatment. An agree-
ment was reached on the minimal criteria needed to
define POR. At least two of the following three cri-
teria had to be present to establish the definition: (1)
Advanced maternal age (>40 years) or any other risk
factor for POR. (2) A previous POR (≤3 oocytes with
a conventional stimulation protocol). (3) An abnormal
ovarian reserve test [i.e. antral follicle count (AFC)
less than 5–7 follicles or anti-Müllerian hormone
(AMH) below 0.5–1.1 ng/ml]. Since 2011 a significant
body of discussion and debate has been published
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regarding needed revisions [6–10]. These points of
discussion and concerns are summarized in Table 1.
The purpose of the present review is to summarize
this discussion and expound several points of the debate.
The cut-off points for age and number of retrieved oo-
cytes, included in the first two criteria, have been re-
cently discussed [10]. In this review, a contemporary
appraisal of the literature is carried out, concerning AFC
and AMH threshold values, oocyte quantity versus qual-
ity, concern regarding over diagnosis and presenting evi-
dence to include established risk factors into the criteria.
Review
POR includes several sub-populations
Poor ovarian response is accepted as a manifestation of
low ovarian reserve and early ovarian aging. The primary
theory being held to explain this process is the depletion
of the ovarian pool of non-growing follicles, including
primordial, intermediate and primary follicles, believed
to be at its maximum in-utero and shrinking gradually
towards menopause. Several mechanisms have been sug-
gested to explain the decline in oocyte quantity and
quality. These include possible differences in germ cell
formation during fetal life, changes in the quality of the
granulosa cells surrounding the oocyte as well as accu-
mulated damage to the oocytes during childhood and re-
productive life [11]. However, the exact mechanism(s)
are still mostly obscure. Thus, any of several possible
mechanisms may underlie POR in different patients and
each suggested treatment mode may have different im-
pact on oocyte quality and some may not improve the
outcome [6].
In this regard, Papathanasiou maintains that women
grouped under the Bologna criteria comprise several
sub-populations with diverse baseline characteristics and
unknown clinical prognosis [8]. For research purposes
this posits potential bias if women from each sub-
population are not recognized and accordingly evenly al-
located between comparison groups. In response to his
suggested stratified randomization by eight sub-
populations, Venetis claims that stratification has several
shortcomings and should be used only when there is
clear evidence supporting such a design [9]. It is prema-
ture at this stage to perform stratified randomization
when there is insufficient data to support such practice
in RCTs on women conforming to the Bologna criteria.
Only ten years ago the original consensus criteria for
the diagnosis of polycystic ovary syndrome (PCOS) were
released [12]. PCOS is a relatively common condition
believed to be caused by several mechanisms, which
need to be clarified and explored. Moreover, it includes
several phenotypes and sub-populations. Yet, this has
not prevented the introduction of simple, clearly defined
and reproducible criteria that paved the way for well-
designed controlled studies, which examined different
treatment modalities. Admittedly, when these criteria for
PCOS were first introduced, concerns over disadvan-
tages of these criteria, specifically related to various phe-
notypes and different sub-groups, have been also raised
and discussed [13, 14]. However, these criticisms did not
prevent the implementation of properly designed trials
with good external validity that evolved into clear con-
sensus on infertility treatment and various aspects of
women’s health related to PCOS patients [15, 16].
Recently, few retrospective studies have evaluated the
Bologna criteria to determine whether they may effectively
identify infertile populations with low ovarian reserve and
diminished chance of success undergoing ART treatment
[17–21]. The live birth rate following conventional stimu-
lation was shown to be similarly low, 6–7 % per started
cycle, in three unrelated studies [18, 19, 21], supporting
the validity of the Bologna criteria for POR, an encour-
aging step toward the adoption of a uniform definition.
Further large scale studies are needed to validate these
results.
AFC and AMH threshold values
Antral follicle count and AMH are considered today
the most informative biomarkers of ovarian reserve
[22]. Their improved performance is the result of sig-
nificantly stronger correlation with non-growing folli-
cles and primordial follicle counts [22]. Although it is
still debatable which of the two biomarkers is super-
ior for ovarian reserve appraisal, both predict poor re-
sponse and cycle cancellation as well as excessive
response and ovarian hyperstimulation syndrome de-
velopment with equivalent levels of accuracy and clin-
ical value [23, 24]. Similarly, they also predict age at
natural menopause, which is a related correlate of
ovarian reserve [25–27]. Both AFC and AMH have
also been tested for their potential to optimize treat-
ment strategies for improving pregnancy outcomes in
ART, and yielded encouraging results [28–30]. For
those reasons they were appropriately chosen to serve
Table 1 Main points of debate and concerns regarding the
Bologna criteria for poor ovarian response
1. Homogeneity of population
2. Cut-off values for
a. Age
b. Number of retrieved oocytes
c. AFC and AMH
3. Risk factors other than age
4. Oocyte quantity versus quality
5. Over diagnosis
6. Large scale validation
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as the third criterion of the Bologna definition of
POR.
Nevertheless, both biomarkers still lack total
consistency, thus flexible cut-off levels of AFC and
AMH to predict POR were included in the Bologna cri-
teria. For AFC, the cut-off values chosen ranged from
less than 5 to less than 7, whereas for AMH the values
were in the range from less than 0.5 to less than 1.1 ng/
mL. Several methodological issues have been raised re-
garding sonographic antral follicle definition (2–5 or 2–
10 mm) and different AMH assays (Immunotech–Beck-
man Coulter and Diagnostic System Laboratories) [31].
More challenging is the fact that the diagnostic perform-
ance of any biomarker of ovarian reserve, including
these two, is methodologically dependent on the preva-
lence of POR in the studied population. The latter could
affect the sensitivity and specificity of either test to de-
tect POR, in turn dictating the chosen threshold. Obvi-
ously, patient selection is crucial when studying POR
occurrence during ART treatment. Liberal policy of
ART employment in POR women, such as in Israel may
diverge from its strict use [32]. These factors should be
well evaluated in prospective targeted future studies with
appropriate external validation in order to reach clearly
defined and reproducible threshold criteria for these
biomarkers.
Oocyte quantity versus quality
The original Bologna criteria did not address the issue of
oocyte quantity versus quality, and this issue remains to
be resolved. Chronological age has been considered as
the best criterion available, although limited, to predict
pregnancy and presumably oocyte quality. Until few
years ago, none of the available ovarian reserve tests, in-
cluding AFC and AMH were shown to predict preg-
nancy or live birth with sufficient accuracy [33, 34].
Moreover, the addition of these tests appears to add no
value to chronological age [22].
In the last few years, well performed studies have
shown a significant association between AMH and live
birth prediction in ART, independent of age [35, 36]. A
large recent review and meta-analysis concluded that it
is probable that AMH has an association with oocyte
quality independent of a woman’s age, but this associ-
ation is likely weak to moderate at best. [37] This may
be helpful when counseling couples before undergoing
fertility treatment. However, its predictive accuracy is
poor, especially when there is evidence to indicate that
live births are possible with very low AMH levels oppos-
ing the use of AMH values alone to withhold treatment
[38].
It should be noted that the contradicting findings of
studies showing an association between AMH and live-
birth and others negating such an association could be
attributed to differences in AMH testing, study design
and patient selection. Until there is an accurate
biomarker that could examine oocyte quality and not
quantity, the task of finding suitable criteria to predict
live-birth would be intricate to accomplish.
The increasing miscarriage rate with advancing fe-
male age has been attributed to a decline in oocyte
quality. A poor response to ovarian hyperstimulation
is often an expression of a decrease in oocyte quan-
tity. Although oocyte quality and quantity both de-
crease as a result of ovarian ageing, it is unclear to
what extent these two processes are correlated to
each other. Miscarriage rate following IVF-ET treat-
ment would be an indirect measure of oocyte quality.
Interestingly, Among women <36 years, miscarriage
rates between poor and normal responders did not
differ, whereas among women ≥ 36 years poor re-
sponders had a significantly increased miscarriage rate
compared to normal responders [39]. These findings
show that women with POR at young age likely have
better oocyte quality as compared to more advanced
age women with comparable POR. Even more, it em-
phasizes the importance of risk factors inclusion into
the definition criteria.
Concern regarding over diagnosis
According to the Bologna criteria one stimulated cycle is
essential to fulfill the second criteria for the diagnosis of
POR. However, patients over 40 years of age or with a
risk factor for POR and an abnormal AFC or AMH
value are classified as “expected POR” before engaging
into treatment. “Expected POR” women, also described
as diminished/low ovarian reserve cases, are usually
urged to go forward for ART without hold at other mo-
dalities of treatment to maximize their suboptimal suc-
cess rate.
Recent large scale studies have shown that the diagno-
sis of diminished/low ovarian reserve as an indication
for ART treatment has increased significantly in the last
few years [40, 41]. This increase has been shown to
over-ride the expected natural raise of average age of
mother at first birth. These results imply that dimin-
ished/low ovarian reserve diagnosis represents over diag-
nosis rather than improved detection [41] and the
addition of diagnostic testing modalities, such as AFC
and AMH, may has contributed to this increase.
What may concern more is the recently reported wide
discrepancy in live-birth rate between women undergoing
ART treatment with diminished/low ovarian reserve or
“expected POR” and those with actual POR. While the live
birth rate was reported to be optimistic in “expected
POR” cases (17–24 % per cycle) [20, 42], it was shown to
be particularly low in actual POR patients (6–7 % per
cycle) [17–19, 21].
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Taken together, the diagnosis of diminished/low ovar-
ian reserve or “expected POR” as an indication for ART
treatment is increasing, while their live birth rate is too
optimistic, questioning the reliability of the diagnosis
and suggesting over diagnosis. Careful and accurate em-
ployment of the Bologna criteria for POR and “expected
POR” diagnosis are crucial to universally adopt and im-
plement these criteria into the daily practice. Further-
more, the inclusion of risk factors into the first criteria
seems to add clarity and reliability of POR definition.
Risk factors of poor ovarian response
In order to reach a common and universal definition of
POR, each one of the three criteria selected in the Bol-
ogna criteria should be simple, clearly defined and re-
producible. Whereas maternal age (≥40 years), previous
POR (≤3 three oocytes with conventional stimulation)
and abnormal ORT (AFC < 5–7 or AMH < 0.5–1.1 ng/
ml) were all fittingly defined in the Bologna criteria, the
risk factors were not [4]. Specific risk factors unequivo-
cally associated with POR were not defined. A want of
well-established risk factors was voiced by us and
adopted later by the ESHRE working group [7, 42].
The recommended list of risk factors for POR in
young women below the age of 40 years was produced
following a comprehensive search of the literature [43].
The list includes medical risk factors as short menstrual
cycle length, single ovary, previous ovarian cystectomy,
chronic smoking, unexplained infertility, previous
chemotherapy and/or radiotherapy treatment. It also in-
cludes genetic risk factors such as family history of pre-
mature menopause, X chromosome derangements and
fragile X mental retardation 1 (FMR1) pre-mutation.
In this review, an emphasis on recent studies, in par-
ticular since the release of the Bologna criteria, has been
made. A special attention was made to examine contem-
porary evidence evaluating these risk factors in relation
to ovarian response to hormonal stimulation, ovarian re-
serve tests, premature ovarian failure (POF) and early
age at menopause as a proxy of accelerated ovarian age-
ing, representing different facets of ovarian reserve
appraisal.
Short menstrual cycle
Shortening of the menstrual cycle heralds the meno-
pausal transition and is associated with inferior IVF re-
sults [44, 45]. Short menstrual cycle was attributed to
low inhibin-B and high FSH levels accelerating follicular
recruitment, dominance and ovulation.
In a prospective observational study Brodin et al. [46]
evaluated a total of 6271 IVF/ICSI treatment cycles, and
recorded that increasing age was associated with a subtle
shortening of menstrual cycles. Menstrual cycle length
was significantly associated with ovarian response to
gonadotropin stimulation, embryo quality, and clinical
pregnancy and live birth rates, independently of age.
In a recent analysis of 2015 oocyte donation cycles
resulting in 3427 embryo transfers, Vassena et al. found
that the shorter the cycle length, the poorer were the re-
sponse to ovarian stimulation in the donors and preg-
nancy rate in the receivers [47].
Taken together, menstrual cycle length seems to have
a role in POR detection, in women undergoing ART
treatment, affecting both oocyte quantity and quality.
Single ovary
Unilateral oophorectomy and ovarian cystectomy have
been both implicated in the decrease of ovarian reserve.
Recently, in a cross-sectional analysis of the Japan
Nurses’ Health Study data were analyzed for 24,152 pre-
and postmenopausal women who were 40 years or older
at the baseline survey [48]. Median age at menopause in
women who had undergone unilateral oophorectomy
was 1.2 years earlier than controls. Single ovary was also
associated with early menopause before 45 years of age
[OR = 3.94] and POF [OR = 3.32].
Similarly, in a cohort study of 23,580 Norwegian
women who were included in the population-based
HUNT2 Survey during the years 1995–1997, women
who had undergone unilateral oophorectomy were sig-
nificantly younger at menopause than women without
unilateral oophorectomy [49]. The relative risk of meno-
pause following unilateral oophorectomy was 1.27.
Ovarian cystectomy
Resection of an ovarian cyst may inadvertently cause
damage to the normal ovarian reserve. Coccia et al. [50]
conducted a prospective longitudinal cohort study of
302 patients who underwent laparoscopy for endometri-
osis between March 1993 and November 2007. They re-
corded menopause in 43 women (14.3 %), of whom
seven went into POF. Women who underwent bilateral
cystectomy were five years younger at menopause than
those who underwent a unilateral operation.
The impact of endometriomas’ resection on ovarian
reserve as determined by serum AMH was a subject to a
meta-analysis of eight studies [51]. Pooled analysis of
237 patients showed a decrease in serum AMH concen-
trations after ovarian cystectomy with weighted mean
difference of –1.13 ng/mL. Although heterogeneity was
high, the results of this analysis support a deleterious ef-
fect of the excision of endometriomas on ovarian
reserve.
In a cohort analysis of 835 women with ovarian insuf-
ficiency, 75 patients underwent ovarian surgery before
the onset of ovarian failure. Of those 75 patients, 66
underwent cystectomy, mostly for endometriomas [52].
The mean age of patients at the time of surgery was
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about 28 years, and the mean interval to the onset of
ovarian failure was about 6 years. The patient’s age at
the time of surgery and the elapsed time to the onset of
ovarian failure were well-correlated, supporting the role
of ovarian cystectomy as a risk factor for the develop-
ment of ovarian insufficiency.
In a recent case–control study on women with POR
aged under 40 years, IVF results and live birth rate were
evaluated to examine whether they depend on the eti-
ology of low ovarian reserve [53]. Clinical pregnancy rate
and live birth rate were significantly impaired in POR
caused by a previous cystectomy of an endometrioma as
compared with POR of unknown etiology.
Taken together, resection of an endometriotic cyst(s)
adversely affects ovarian reserve, supporting its inclusion
as an independent risk factor for POR. Data presented
support an association with both oocyte quantity and
quality.
Chronic smoking
Cigarette smoking is the most established and consist-
ently observed risk factor for younger age at menopause
with a clear dose-response association [54]. In a pro-
spective cohort study of 3545 middle aged Australian
women, a 21-year follow-up revealed that women who
smoked cigarettes were more likely to experience earlier
menopause than non-smokers. The impact of smoking
on earlier age at menopause was independent of other
variables suggesting a causal relationship [55]. Further-
more, in the largest population-based study of AMH, in-
volving 2320 premenopausal women, current but not
past smoking was associated with a lower age-specific
AMH percentile [56].
During a 14-year follow-up of the Penn Ovarian Aging
Study [57], of 401 women 39.2 % were smokers at the
mean entry age of 41.5 years, AMH was a strong pre-
dictor of median time to menopause. Smoking signifi-
cantly shortened the time to menopause. Combined, age
and smoking were found as independent contributors to
the predictions of AMH levels.
In an ART setting, Caserta et al. [58] found in a group
of 102 smokers lower AFC and higher basal FSH level as
compared to 194 non-smokers. Furthermore, the num-
ber of pack-years was negatively correlated to AFC and
positively correlated to FSH levels. Studying 80 current
active smokers with 197 non-smokers, Fréour et al. [59]
found the same results regarding AMH and AFC and
also that smokers also experienced poorer IVF outcome
with decreased ovarian response, reduced top embryo
proportion, lower pregnancy and live birth rates.
In another report, Fréour et al. [60] studied the mor-
phokinetics of embryos after IVF-ICSI in 135 women, 23
smokers and 112 non-smokers. Time-lapse analysis
showed that most cleavage events occurred significantly
later in smokers than in nonsmokers, leading to poor
cycle outcome in smokers.
There is but one report which does not support detri-
mental effect of smoking on the ovary and ART results
[61], but it did not examine the effect of smoking with
regards to patients with low ovarian reserve. Thus,
smoking should stand as a discrete risk factor for POR.
Taken together, numerous studies support chronic
smoking as a risk factor for POR, affecting both oocyte
quantity and quality.
Unexplained infertility
This factor is the least explored risk factor, among the 9
risk factors presented. In the last few years, to the best
of our knowledge, no study has been performed to target
the association between unexplained infertility and low
ovarian reserve or POR.
In an earlier cohort study of 2392 women, analysis was
performed using age at menopause as proxy for acceler-
ated ovarian ageing. Several measures related to sub-
fertility were analyzed [62]. All measures examined were
significantly associated with early menopause supporting
the notion that both are expressions of the same acceler-
ated ovarian ageing.
Randolph et al. [63] conducted a prospective observa-
tional study in a small group of women rigorously de-
fined as unexplained infertility. Their early follicular
FSH was significantly higher compared to a matched
control, pinpointing to diminished ovarian reserve.
In another study of infertile women undergoing hor-
monal stimulation for IVF, a prospective cohort of pa-
tients with unexplained and mild male factor sub-
fertility was compared to a large retrospective cohort of
women with unexplained, mild male and tubal sub-
fertility [64]. In both cohorts, women with idiopathic or
mild male sub-fertility showed POR while those with
tubal factor did not.
Taken together, available studies support the notion
that unexplained infertility is a risk factor for low ovar-
ian reserve and POR.
Previous chemotherapy and/or radiotherapy treatment
This is a well established risk factor for POR and early
ovarian aging, leading to the recent advice to young
women before chemotherapy or pelvic radiotherapy to
consider novel fertility preservation measures before
starting their medical treatment.
In a cross-sectional analysis of data 71 cancer survi-
vors aged 15–39 years were compared to 67 same age
healthy, unexposed women and to 69 regularly menstru-
ating women of late-reproductive age (40–52 years) [65].
Early follicular ovarian reserve tests (AFC, AMH and
FSH), were significantly inferior in exposed as compared
to unexposed women. Alkylating agent dose score was
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significantly associated with increased levels of FSH and
decreased levels of AMH. Exposure to pelvic radiation
was also associated with impairment in FSH, AMH,
AFC and ovarian volume. AMH was similar in women
previously exposed to high-dose cancer therapy and
40–42 year old controls. All in all, among cancer sur-
vivors ovarian reserve tests, endocrine and sono-
graphic, were impaired, in a dose-dependent manner,
compared to unexposed women of similar age.
Krawczuk-Rybak et al. [66] studied 33 young female
cancer survivors who were treated previously (6–11
years earlier), for a period above 5 years and compared
them to 34 healthy controls. The group of survivors was
divided according to the risk of gonadotoxicity into low
(LR), median (MR) and high risk (HR) groups. Serum
AMH level at baseline was significantly lower in the HR
group compared to the control and the LR +MR groups.
In the HR group AMH level continued to decrease and
FSH to increase progressively after 5 years. In the LR +
MR group, the levels of AMH and FSH were normal at
baseline, but after 5 years AMH decreased and FSH in-
creased indicating that chemotherapy during childhood
and adolescence causes serious and progressive loss of
ovarian reserve. High risk gonadotoxic treatment in this
setting may thus lead to POF.
In a recent cross-sectional study 53 girls at median age
13.9 years who survived cancer were recruited at least
1 year from completion of cancer therapy and tested for
ovarian reserve [67]. Thirty-one of the 53 patients
(58 %) had AMH value <1 ng/mL and 17 (32 %) had
FSH value of >12 IU/mL showing low ovarian reserve.
Patients exposed to high-risk chemotherapy or pelvic ir-
radiations were at significantly higher risk for early ovar-
ian ageing. AMH level was also significantly lower in the
patients who had delayed puberty emphasizing the dele-
terious impact of chemotherapy on ovarian reserve in
childhood and adolescence.
Family history of premature menopause
In a cross-sectional study, Bentzen et al. [68] obtained
data on a prospective cohort of 863 health care workers
aged 20–40 years who underwent ovarian reserve test-
ing. Of these 527 disclosed their mothers’ age at natural
menopause. A significant correlation was found between
the mother’s age at natural menopause and daughters’
AFC and AMH values. The rate of decline in AFC and
AMH was also associated with age at maternal meno-
pause, supporting a genetic component in early meno-
pause and low ovarian reserve.
In a recent study two groups were evaluated. The first
consisted of 164 mother–daughter pairs. The second in-
cluded 150 women, with regular menstrual cycles, in
whom AMH and mother’s age at natural menopause
were recorded prior to a 12-year follow-up period
awaiting the appearance of natural menopause [26]. Both
age and mother’s age at natural menopause were signifi-
cantly associated with daughter’s time to menopause in
the two cohorts. Multivariate analysis suggested a 47 %
improvement in predictive accuracy of daughter’s age at
natural menopause by adding AMH to the model of age
and mother’s age at natural menopause.
Taken together, mother’s age at natural menopause
seems to have a genetic role in predicting daughters’
ovarian reserve and therefore ought to be employed as a
risk factor for POR.
X chromosome derangements
This is a well established risk factor for POF, diminished
ovarian reserve, POR and early menopause. Women
with structural and numerical abnormalities of the X
chromosome make up the largest subgroup with primary
ovarian insufficiency. Reproductive disorders in women
with Turner’s syndrome (45,X) arise from lack of all or
part of the X chromosome. Although one X chromo-
some is sufficient to allow ovarian differentiation, oo-
cytes need two active X chromosomes. In women with
mosaic Turner’s syndrome (45,X/46,XX), menarche can
take place and menstruation may continue for several
years [69]. Other genetic derangements which could in-
volve the X chromosome are monosomy, trisomy, inver-
sion or translocation. Genetic mechanisms include
reduced gene dosage and non-specific chromosome ef-
fect impairing meiosis, decreasing the pool of primordial
follicles and increasing atresia due to apoptosis or failure
of follicle maturation.
In a prospective case-control study, 18 women who
experienced recurrent miscarriages and had mosaicism
of X-chromosome aneuploidies were compared to two
control groups, 20 women with a balanced structural
autosomal rearrangement and 135 women without
chromosomal abnormalities [70]. Women with X-
chromosome mosaicism without a balanced autosomal
structural rearrangement had a significantly higher inci-
dence of POR, occurring in 44.4 % of cases as compared
to 9.6 % of controls. In comparison with controls with-
out chromosomal abnormalities, women with a balanced
autosomal structural rearrangement also had higher inci-
dence of POR, but the groups were too small for the dif-
ference to reach statistical significance.
The role of genes as determinants of ovarian aging re-
ceives growing attention in the last decade and the infor-
mation is rapidly expanding. Methods which are used to
elucidate the role of specific genes involved in ovarian
aging include comparative genomic hybridization
(CGH), array CGH (aCGH), genomewide linkage ana-
lysis, candidate gene-association studies, genome-wide
association studies and transgenic animal models. This
have been recently reviewed [71] and successfully
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employed in cases of idiopathic POF involving X
chromosome to detect partial Xp duplication and Xq de-
letion in spite of a cytogenetically 46,XX normal karyo-
type [72–74].
Fragile X mental retardation 1 pre-mutation
The number of CGG repeats in the X-linked gene
known as fragile X mental retardation 1 (FMR1) can be
responsible for various clinical conditions. Normal
alleles have 26–34 repeats of the trinucleotide, whereas
the full mutation has >200 repeats and is responsible for
the clinical features of fragile X syndrome, which is the
commonest cause of inherited mental retardation or
genetically caused autism. Premutation alleles range
from 55 to 199 CGG repeats and can cause either a
neurological degenerative disorder in male carriers or
premature ovarian failure in approximately 13 % of the
female carriers. In addition, premutation alleles are un-
stable and can be expanded to full mutation over several
generations [75, 76].
It has been reported that women carrying a premuta-
tion allele have a higher likelihood of experiencing
menopause approximately 5 years earlier and having
higher levels of FSH for any age over 30 years, compared
with non-carriers. However, the relationship between the
number of CGG counts and age of menopause is not
linear and it appears that women with 80–100 repeats
are at greater risk of POF than women with over 100 re-
peats [76].
In an IVF-PGD setting for fragile X syndrome analysis,
27 patients with the FMR1 mutation (5 with full muta-
tion, 22 with premutation) undergoing 79 cycles were
compared to 33 controls with other genetic diseases
undergoing 108 treatment cycles [77]. FMR1 mutation
carriers required significantly higher doses of gonadotro-
pins, which nevertheless yielded significantly fewer num-
bers of oocytes, indicating diminished ovarian reserve in
FMR1 carriers.
In a cohort of 535 infertile women < 42 years of age
with low ovarian reserve, defined by elevated FSH or
poor response to hormonal stimulation, participants
were analyzed for FMR1 premutation (55–200 repeats)
and intermediate alleles (45–54 repeats) and compared
to 521 controls [78]. The frequencies of the premutation
as well as intermediate alleles were significantly higher
in women with low ovarian reserve compared to con-
trols, 1.3 % vs 0.2 % for premutation and 3.2 % vs 0.2 %,
for intermediate alleles.
It is still unclear whether the grey zone of intermediate
alleles with up to 54 CGG counts has an association
with low ovarian reserve and early ovarian aging. Al-
though primary reports indicated an increased risk for
the development of premature ovarian failure and im-
paired ovarian reserve tests [79–81], recent well
controlled studies found no negative effect of
intermediate-sized CGG repeats on ovarian stimulation
and clinical outcome in either oocyte donation setting
[82], development of premature ovarian failure [83] or
age at natural menopause [84].
The debate on risk factors inclusion
It seems that the nine situations discussed above have
evidence to support their employment as risk factors for
the development of POR in the ART setting. Three of
these risk factors, including short menstrual cycle, endo-
metriotic cystectomy and chronic smoking have evi-
dence to support their association with both quantity as
well as quality of the retrieved oocytes, affecting embryo
quality and pregnancy achievement. Prospective targeted
studies are encouraged to strengthen these associations.
The other six factors have evidence to support their role
in the quantity of oocytes and more studies are needed
to examine their association with oocyte quality. Includ-
ing risk factors in the Bologna criteria should yield spe-
cific associations between oocyte quantity and quality.
Most of these factors are easy to detect by taking simple
medical history, making their use easily applicable. Un-
explained infertility seems to be the least explored risk
factor for POR and future well designed studies are
needed to further explore this association.
Since the release of the Bologna criteria few studies
have evaluated their validity, following conventional
stimulation in ART. The risk factors included were dif-
ferent among these studies [18–21]. While part of these
studies did not note which risk factors were looked for
[18, 21], one study included ovarian endometrioma, pre-
vious ovarian surgery, previous chemotherapy, genetic
abnormalities and shortening of the menstrual cycle as
risk factors [19] and another included only history of
ovarian surgery or endometrioma [20]. These differences
in risk factors inclusion demonstrate lack of clarity in
the Bologna criteria for POR which may adversely affects
their reproducibility and reliability. The need for
standardization of risk factors seems to be essential.
It might be argued that any of these risk factors could
not solely identify or predict young POR patients with
high accuracy. However, adding a previous POR (second
criterion) or a pathological ovarian reserve test (third
criterion) to a proven risk factor would fulfill the Bol-
ogna criteria for POR. Similarly, previous POR (second
criterion) or a pathological ovarian reserve test (third
criterion) cannot solely predict POR with high accuracy.
It was clearly cited in the Bologna original report on
POR definition that one-third of previous poor re-
sponders will have a normal response in subsequent cy-
cles [84]. Moreover, while AMH and AFC are the most
reliable and accurate markers of ovarian reserve [85, 86],
their overall performance in the prediction of poor
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response is less than optimal [33]. Most importantly, this
was the original idea when employing the same logical
approach for PCOS diagnostic criteria; each criterion
used alone is insufficiently accurate to identify women
with the highest probability of being a real POR, and
more than one criterion should be contemporaneously
present in each subject.
It is also implicit that some of the risk factors are
well established, while others are still controversial
and some novel candidates may be identified in the
near future [7, 10], but this should not hold back the
incorporation of the proven risk factors into the cri-
teria. A second meeting of an expert working group
on POR definition may be organized to discuss which
risk factors have enough evidence to be included in
the criteria.
Accurate definition of POR or “expected POR” in
women below the age of 40 may contribute materially to
a more appropriately tailored treatment approach. In
addition, it may open new doors for the incorporation of
young POR women into future targeted trials testing
new strategies or modalities of treatment. Most import-
antly, it may enable health providers to recommend, at
appropriate biological time, early pregnancy achievement
or fertility preservation in women at risk.
Conclusions
Poor ovarian response to conventional stimulation com-
prises several sub-populations of low ovarian reserve
with diverse baseline characteristics. This should not
preclude steps to adopt a uniform definition of POR,
one of the main challenges of modern reproductive
medicine. The Bologna criteria for the definition of POR
have introduced a key step forward. However, the dis-
cussion is still ongoing regarding age, number of re-
trieved oocytes as well as AFC and AMH cut-off levels,
adopted by the ESHRE consensus criteria. Concern has
also been raised regarding absent association with oocyte
quality and presumably pregnancy achievement as well
as over diagnosis when adopting these criteria. Large
scale validation studies are still lacking to universally
adopt the Bologna POR criteria. Time has come to in-
clude established risk factors into the criteria. This will
lead to a more simple, reproducible and reliable defin-
ition of POR. Moreover, the addition of risk factors for
POR, especially in young women, may avoid confusion,
yield specific associations with oocyte quality versus
quantity and prevent over diagnosis.
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